New Malaria Vaccine Candidate Shows Promise in Preclinical Trials, Moving Toward Human Testing

A promising new malaria vaccine candidate has advanced in preclinical trials, offering hope for more effective protection against the deadly disease. MedicalXpress reports that an international team from Canada, the US, and the Netherlands developed the vaccine using the Canadian Light Source at the University of Saskatchewan. Published in Nature Communications on March 11, the study fused two potent proteins from the malaria parasite identified in blood samples of people with natural immunity, eliciting stronger immune responses than individual proteins alone.

Lead author Danton Ivanochko from Toronto's Hospital for Sick Children stated, "Our long-term goal is to eliminate malaria by designing a vaccine that is more effective than the ones currently on the market." Structural mapping confirmed antibodies bind effectively to the target proteins, a key step reducing risks before costly human trials. If further tests succeed, clinical trials could begin in a few years, potentially aiding global efforts where 282 million cases and 610,000 deaths occurred in 2024, per World Health Organization data cited in the report.

Complementing this, University of Nottingham researchers identified Aurora-related kinase 1 (ARK1) as a critical protein in the parasite's cell division, Healthandme.com detailed. Disabling ARK1 halted reproduction in lab tests, highlighting it as a target for future vaccines or drugs, distinct from human cell versions. Senior author Rita Tewari called the finding exciting amid rising drug resistance threatening elimination goals.

On the policy front, Malaria No More hosted a Congressional Breakfast on March 16, as noted by the George W. Bush Institute, honoring US lawmakers for supporting next-generation malaria tools including vaccines. Speakers emphasized American innovation's role in saving lives and boosting economies. Meanwhile, Vax-Before-Travel updated that as of March 2026, WHO and EMA recommend Mosquirix and R21/Matrix-M vaccines for travelers to endemic areas, though unavailable routinely in the US outside trials.

These developments underscore momentum against malaria, which claims most young lives in Africa, even as WHO notes vaccines averted millions of cases last year. With preclinical breakthroughs and sustained funding, experts eye accelerated progress toward eradication.

This content was created in partnership and with the help of Artificial Intelligence AI